JİNEKOLOJİK ONKOLOJİ CERRAHİSİNDE HIPEC TEDAVİSİNİN YERİ

Yıl 2014, Cilt: 17 Sayı: 1, 0 - 0, 01.01.2014

Macit Avras Nedim Tokgözoğlu

Öz

Birçok kanser abdomen ve pelvis içerisindeki organlardan kaynaklanmaktadır ve üç farklı yol ile yaylırlar. Bunlar; hematojen, lenfatik
ve transçölemik yoldur. Çok sayıda hastada hastalık progresyonu, rezeksiyon bölgesi veya peritoneal yüzeyden olmaktadır.
Peritoneal yayılan kanserlerde çoğunlukla ölüme peritoneal karsinomatozis sebep olduğu için, peritonun çıkarılması bu hastaların
sağkalımına olumlu yönde etki edecektir. Buna ek olarak kemoterapötik ilaçların intraperitoneal olarak uygulanması ile tümör üzerinde
direkt olarak yüksek ilaç konsantrasyonlarına ulaşılır. Hipertermik intraperitoneal kemoterapi, peritonektomi ve sitoredüktif
cerrahi gerçekleştirildikten sonra peroperatif intraperitoneal kemoterapi uygulanmasıdır. Cerrahi ile rezidüel tümör dokusunu
mikroskobik düzeye indirmek amaçlanmalıdır. Literatür bulguları gösteriyor ki sitoredüktif cerrahi ve hipertermik intraperitoneal
kemoterapi kabul edilebilir toksisite oranları ile uygulanabilirdir. Morbidite ile ilişkili en önemli faktör, uygulanan barsak rezeksiyonu
sayısı ve kemoterapötik ilacın serozal hasarın iyileşmesi üzerine olumsuz etkisi gibi görünmektedir. Sonuç olarak yapılan
çalışmalara baktığımızda hipertermik intraperitoneal kemoterapi tedavisinin gelecekte over tümörleri ve peritoneal yüzeyel karsinomatoziste,
primer veya sekonder olarak geniş uygulama alanı bulacağını düşünmekteyiz. Bu konuda ki deneyimimiz son derece
kısıtlı olmasına rağmen gelecek için umutlu bir yöntem olduğunu ifade edebiliriz. Ancak yöntemin uygulanmasında tekonoloji
gereği, operasyonu uzun sürmesi, deneyimli mutidisipliner bir ekip ile çok iyi bir postoperatif bakım gerektiği unutulmamalıd

Anahtar Kelimeler

HIPEC, Jinekolojik Onkoloji, Kanser, Kemoterapi

THE ROLE OF HIPEC THERAPY IN GYNECOLOGIC ONCOLOGIC SURGERY

Öz

Many types of cancer originate from the organs in the abdominal and pelvic regions, and they spread via 3 different routes:
namely, hematogeneous, lymphatic and transcoelomic. The dissemination of the cancer tends to occur via the resection area
or peritoneal surface in many patients. Because peritoneal carcinomatosis is the most common cause of death in malignancies
disseminated via the peritoneal route, removal of the peritoneum will have a positive impact on the survival of patients.
Additonally, intraperitoneal instillation of chemotherapeutic medications reaches high concentrations with direct effect on
the tumor. Hyperthermic intraperitoneal chemotherapy (HIPEC) refers to application of perioperative chemotherapy following
peritonectomy and cytoreductive surgery. Surgery should aim to reduce residual tumor burden to microscopic levels. The
available literature reveals that cytoreductive surgery and HPEC can be performed within acceptable toxicity ratios. The most
important factors with potential effect on morbidity appear to be the number of bowel resections and the adverse impact of
chemotherapy on healing of the serosal damage. In conclusion, on the basis of available data in the literature, we believe that
HIPEC treatment will have widespread utility in primary or secondary management of ovarian tumors and peritoneal superficial
carcinomatosis in the future. Although we have quite limited experience on this topic, we can state that it is a promising method
in the future. However, it should be noted that an experienced multi-diciplinary team providing excellent postoperative care is
mandatory owing to the high technology required in application of this method and the relatively long duration of the surgery

Anahtar Kelimeler

HIPEC, Gynecologic Oncology, Cancer, Chemotherapy

Kaynakça

• 1. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950–1955.
• 2. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34–43
• 3. Lhomme C, Morice P, Planchamp F, et al. Clinical practice guidelines 2008 for the surgical treatment, medical fi rst-line and consolidation treatments of patients with epithelial ovarian cancer—Update. According to the methodology of Standards, Options: Recommendations (SOR). Bull Cancer 2008; 95: 881– 886.
• 4. Paul H. Sugarbaker, FACS, FRCS technical handbook fort he integration of cytoreductive surgery and perioperative intraperitoneal chemotherapy into the surgical management of gastrointestinal and gynecologic malignancy 5th edition March 2010.
• 5. Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P: Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer, Cancer Res 1990; 50: 5790-5794.
• 6. Esquivel J, Sugarbaker PH: Elective surgery in recurrent colon cancer with peritoneal seeding: When to and when not to proced. (Editorial). Cancer Therapeutics 1998; 1:321-325.
• 7. Gerestein CG, Damhuis RA, Burger CW, et al. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review [review]. Gynecol Oncol 2009;114:523–527.
• 8. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004; 95: 273–280.
• 9. Helm CW, Richard SD, Pan J, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: fi rst report of the HYPER-O registry. Int J Gynecol Cancer 2010; 20: 61–69.
• 10. Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 2009; 14: 683–694.
• 11. Criteria NCICT for adverse events (CTCAE) version 4.0. Available at: http://evs. nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed June 3, 2012.
• 12. Fagotti A, Costantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol 2011;122:221–225.
• 13. Chua TC, Robertson G, LiauwW, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 2009; 135:1637–1645.
• 14. Marcello Deraco, Shigeki Kusamura, Salvatore Virzì, Francesco Puccio, Antonio Macrì, Ciro Famulari, Massimiliano Solazzo, Serena Bonomi, Domenico Rosario Iusco, Dario Baratti. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multiinstitutional phase-II trial Gynecologic Oncology 2011; 122: 215–220.
• 15. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, AbuRustum NR, Levine DA, et al. Improved progressionfree and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009; 114: 26–31.
• 16. Bakrin N, Cotte E, Golfi er F, Gilly F.N, Freyer G, Helm W, Glehen O, BerederJ.M. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients Ann Surg Oncol 2012;19: 4052–4058.
• 17. Roviello F, Pinto E, Corso G, Pedrazzani C, Caruso S, Filippeschi M, Petrioli R, Marsili S et al. Safety and Potential Benefi t of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Carcinomatosis From Primary or Recurrent Ovarian Cancer Journal of Surgical Oncology 2010; 102: 663–670.
• 18. Fagotti A, Costantini B, Petrillo M et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case–control study on survival in patients with two year follow-up Gynecologic Oncology 2012; 127: 502–505.
• 19. Ansaloni L, Agnoletti V, Amadori Ş.A et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy(HIPEC) in patients with advanced epithelial ovarian cancer International Journal of Gynecological Cancer 2012; 22(5).
• 20. Deraco M, Virzı S, Iusco DR et al. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-instutional study BJOG Gynaecological Oncology 2012;119:800-809.
• 21. Deraco M, Rossi CR, Pennacchioli E, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001; 87: 120–126.
• 22. Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004; 28: 1040–1045.
• 23. Rufi an S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006; 94: 316–324.
• 24. Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006; 32: 671–675.
• 25. Helm CW, Randall-Whitis L, Martin RS 3rd, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 2007; 105: 90–96.
• 26. Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients [see comment]. World J Surg 2007; 31: 1813–1820.
• 27. Bristow RE, Puri I, Chi DS, et al. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112: 265–274.
• 28. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009; 16: 1324–1330.